Terms: = Lymphoma AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Treatment
8182 results:
1. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
Gao Y; He H; Li X; Zhang L; Xu W; Feng R; Li W; Xiao Y; Liu X; Chen Y; Wang X; Bai B; Wu H; Cai Q; Li Z; Li J; Lin S; He Y; Ping L; Huang C; Mao J; Chen X; Zhao B; Huang H
Signal Transduct Target Ther; 2024 May; 9(1):121. PubMed ID: 38755119
[TBL] [Abstract] [Full Text] [Related]
2. M6A-induced transcription factor IRF5 contributes to the progression of cervical cancer by upregulating PPP6C.
Hou PX; Fan Q; Zhang Q; Liu JJ; Wu Q
Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13868. PubMed ID: 38745265
[TBL] [Abstract] [Full Text] [Related]
3. Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers.
Georgievski A; Bellaye PS; Tournier B; Choubley H; Pais de Barros JP; Herbst M; Béduneau A; Callier P; Collin B; Végran F; Ballerini P; Garrido C; Quéré R
Cell Death Dis; 2024 May; 15(5):328. PubMed ID: 38734740
[TBL] [Abstract] [Full Text] [Related]
4. Multiomics analysis identifies oxidative phosphorylation as a cancer vulnerability arising from myristoylation inhibition.
Beauchamp E; Gamma JM; Cromwell CR; Moussa EW; Pain R; Kostiuk MA; Acevedo-Morantes C; Iyer A; Yap M; Vincent KM; Postovit LM; Julien O; Hubbard BP; Mackey JR; Berthiaume LG
J Transl Med; 2024 May; 22(1):431. PubMed ID: 38715059
[TBL] [Abstract] [Full Text] [Related]
5. Oxidative Stress: An Intersection Between Radiation and Sulfur Mustard Lung Injury.
Day BJ
Disaster Med Public Health Prep; 2024 May; 18():e86. PubMed ID: 38706344
[TBL] [Abstract] [Full Text] [Related]
6. The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability.
Abad E; Sandoz J; Romero G; Zadra I; Urgel-Solas J; Borredat P; Kourtis S; Ortet L; Martínez CM; Weghorn D; Sdelci S; Janic A
J Exp Clin Cancer Res; 2024 Apr; 43(1):127. PubMed ID: 38685100
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.
Bijou I; Liu Y; Lu D; Chen J; Sloan S; Alinari L; Lonard DM; O'Malley BW; Wang M; Wang J
PLoS One; 2024; 19(4):e0289902. PubMed ID: 38683834
[TBL] [Abstract] [Full Text] [Related]
8. Human Placenta-Derived Mesenchymal Stem Cells Improve Neurological Function in Rats with Intrauterine Hypoxic-Ischaemic Encephalopathy by Reducing Apoptosis and Inflammatory Reactions.
Zhao YQ; Xu YY; Zheng YM; Han F; Zhang Y; Pan RL; Chen JR; Hao YM; Yang LW
Front Biosci (Landmark Ed); 2024 Apr; 29(4):139. PubMed ID: 38682178
[TBL] [Abstract] [Full Text] [Related]
9. Assessment of the
Nasr GM; Thawabieh OM; Talaat RM; Moawad M; El Hamshary MO
Front Biosci (Landmark Ed); 2024 Apr; 29(4):162. PubMed ID: 38682177
[TBL] [Abstract] [Full Text] [Related]
10. MNDA, a PYHIN factor involved in transcriptional regulation and apoptosis control in leukocytes.
Bottardi S; Layne T; Ramòn AC; Quansah N; Wurtele H; Affar EB; Milot E
Front Immunol; 2024; 15():1395035. PubMed ID: 38680493
[TBL] [Abstract] [Full Text] [Related]
11. Artemisinin Confers Cytoprotection toward Hydrogen Peroxide-Induced Cell Apoptosis in Retinal Pigment Epithelial Cells in Correlation with the Increased Acetylation of Histone H4 at Lysine 8.
Yang C; Ge L; Yu X; Lazarovici P; Zheng W
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675608
[TBL] [Abstract] [Full Text] [Related]
12. Hyper-N-glycosylated SEL1L3 as auto-antigenic B-cell receptor target of primary vitreoretinal lymphomas.
Elbert M; Neumann F; Kiefer M; Christofyllakis K; Balensiefer B; Kos I; Carbon G; Kaddu-Mulindwa D; Bittenbring JT; Fadle N; Regitz E; Fend F; Bonzheim I; Thurner L; Bewarder M
Sci Rep; 2024 Apr; 14(1):9571. PubMed ID: 38671086
[TBL] [Abstract] [Full Text] [Related]
13. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas.
Lou SY; Zheng FL; Tang YM; Zheng YN; Lu J; An H; Zhang EJ; Cui SL; Zhao HJ
Life Sci; 2024 Jun; 347():122662. PubMed ID: 38670450
[TBL] [Abstract] [Full Text] [Related]
14. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.
Diepstraten ST; Yuan Y; La Marca JE; Young S; Chang C; Whelan L; Ross AM; Fischer KC; Pomilio G; Morris R; Georgiou A; Litalien V; Brown FC; Roberts AW; Strasser A; Wei AH; Kelly GL
Cancer Cell; 2024 May; 42(5):850-868.e9. PubMed ID: 38670091
[TBL] [Abstract] [Full Text] [Related]
15. Web-based cognitive rehabilitation intervention for cancer-related cognitive impairment following chemotherapy for aggressive lymphoma: protocol for a randomised pilot trial.
Gates P; Green HJ; Gough K; Dhillon H; Vardy JL; Dickinson M; Guarnera J; Krishnasamy M; Livingston PM; White V; Ugalde A; Caeyenberghs K
BMJ Open; 2024 Apr; 14(4):e081084. PubMed ID: 38653511
[TBL] [Abstract] [Full Text] [Related]
16. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
Wu D; Zeng X; Zhao Y; Qin M; Gong P
Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
[TBL] [Abstract] [Full Text] [Related]
17. Transcriptome analysis of Burkitt lymphoma cells treated with anti-convulsant drugs that are inhibitors of Epstein-Barr virus lytic reactivation.
Gorres KL; Reineke DM; Miller G
PLoS One; 2024; 19(4):e0299198. PubMed ID: 38635661
[TBL] [Abstract] [Full Text] [Related]
18. Different Levels of Therapeutic Strategies to Recover the Microbiome to Prevent/Delay Acute Lymphoblastic Leukemia (ALL) or Arrest Its Progression in Children.
Aronica TS; Carella M; Balistreri CR
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612738
[TBL] [Abstract] [Full Text] [Related]
19. Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells.
Camoglio C; Balla J; Fadda P; Dedoni S
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611871
[TBL] [Abstract] [Full Text] [Related]
20. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
[Next]
